{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"73.3","value":"19.1"},{"groupId":"OG001","spread":"44.7","value":"24.5"},{"groupId":"OG002","spread":"68.8","value":"39.2"},{"groupId":"OG003","spread":"31.7","value":"23.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"4"}],"units":"Participants"}],"description":"Serum samples were collected from the participants at the defined timepoints. Cmax was determined using standard non-compartmental methods.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants who weighed \\>= 35 kg were administered durvalumab 20 mg/kg IV in Cycle 1 followed by durvalumab in combination with tremelimumab 1 mg/kg IV in Cycles 2-5 every 28 days. From Cycle 6 onwards participants were administered durvalumab 20 mg/kg every 28 days until clinical or confirmed disease progression or until any of other discontinuation criterion was met, whichever occurred first.","id":"OG000","title":"Arm A (>= 35 kg): Durvalumab 20 mg/kg + Tremelimumab 1mg/kg"},{"description":"Participants who weighed \\>= 35 kg were administered durvalumab 30 mg/kg IV in Cycle 1 followed by durvalumab in combination with tremelimumab 1 mg/kg IV in Cycles 2-5 every 28 days. From Cycle 6 onwards participants were administered durvalumab 20 mg/kg every 28 days until clinical or confirmed disease progression or until any of other discontinuation criterion was met, whichever occurred first.","id":"OG001","title":"Arm A (>= 35 kg): Durvalumab 30 mg/kg + Tremelimumab 1mg/kg"},{"description":"Participants who weighed \\< 35 kg were administered durvalumab 20 mg/kg IV in Cycle 1 followed by durvalumab in combination with tremelimumab 1 mg/kg IV in Cycles 2-5 every 28 days. From Cycle 6 onwards participants were administered durvalumab 20 mg/kg every 28 days until clinical or confirmed disease progression or until any of other discontinuation criterion was met, whichever occurred first.","id":"OG002","title":"Arm B (< 35 kg): Durvalumab 20 mg/kg + Tremelimumab 1mg/kg"},{"description":"Participants who weighed \\< 35 kg were administered durvalumab 30 mg/kg IV in Cycle 1 followed by durvalumab in combination with tremelimumab 1 mg/kg IV in Cycles 2-5 every 28 days. From Cycle 6 onwards participants were administered durvalumab 20 mg/kg every 28 days until clinical or confirmed disease progression or until any of other discontinuation criterion was met, whichever occurred first.","id":"OG003","title":"Arm B (< 35 kg): Durvalumab 30 mg/kg + Tremelimumab 1mg/kg"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"The PK analysis set included all participants who received at least 1 dose of study treatment per the CSP for whom any post-dose data were available who did not violate or deviate from the CSP in ways that would significantly affect the PK analysis. Only data from the participants analyzed were reported.","reportingStatus":"POSTED","timeFrame":"Pre-infusion and post-infusion on Cycle 2 Day 1, Cycle 2 Day 8, Cycle 2 Day 15, pre-infusion and post-infusion in Cycle 3, 4, and 5","title":"Dose-Finding Phase: Cmax of Tremelimumab","type":"PRIMARY","unitOfMeasure":"mcg/mL"}